Business
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and ...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025\n\n\n\n\n\n\n Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3\n \n\n\n\n\n\n The pivotal Phase 3 study of Bria-IMT+CPI in advanced metastatic breast cancer is ongoing with an interim analysis expected in 1H2026\n \n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, will be presenting positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS\n \n ®\n \n ) taking place December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.\n \n\n “Our survival and biomarker data at SABCS is very encouraging because it underscores the potential of our novel immunotherapy and precision medicine to treat cancer patients,” stated William V. Williams, MD, BriaCell’s President & CEO. “We remain committed to improve survival and clinical outcomes in cancer patients whose medical needs remain unmet.”\n \n\n “We are extremely pleased with biomarker and patient subgroup data suggesting their use for identifying patients who are most likely to benefit from our treatment,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer.\n \n\n The details of the poster presentations are listed below.\n \n\n\n Late-Breaking Abstract Number:\n \n 3688\n \n\n Presentation Number:\n \n PS1-13-22\n \n\n Presentation Title:\n \n Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial\n \n\n Poster Presentation Date/Time:\n \n Wednesday, December 10, 2025, 12:30 PM - 2:00 PM\n \n\n A pooled interim analysis of 116 patients with available MHC subtyping in the ongoing pivotal phase III study demonstrated an excellent safety profile, improved progression-free-survival (PFS) n HR+/HER-2 and HER2- low subtypes an...